Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 741–750 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 741
- Medicine slug
- iloperidone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
96%
- Numeric value
- 96
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb0fcfd-e4e8-4fb1-9635-901dc9446235 (opens source in a new tab)
Iloperidone label
Version not recorded · Effective date not recorded
The relative bioavailability of the tablet formulation compared to oral solution is 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f60b40-3fca-11de-8f56-0002a5d5c51b (opens source in a new tab)
Iloperidone label
Version not recorded · Effective date not recorded
The relative bioavailability of the tablet formulation compared to oral solution is 96%.
Projected row 742
- Medicine slug
- iloperidone
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb0fcfd-e4e8-4fb1-9635-901dc9446235 (opens source in a new tab)
Iloperidone label
Version not recorded · Effective date not recorded
Absorption Iloperidone is well absorbed after administration of the tablet with time to peak plasma concentrations (Tmax) occurring within 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f60b40-3fca-11de-8f56-0002a5d5c51b (opens source in a new tab)
Iloperidone label
Version not recorded · Effective date not recorded
Absorption Iloperidone is well absorbed after administration of the tablet with time to peak plasma concentrations (T max ) occurring within 2 to 4 hours.
Projected row 743
- Medicine slug
- iloperidone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1340-2800 L
- Numeric value
- 1,340
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb0fcfd-e4e8-4fb1-9635-901dc9446235 (opens source in a new tab)
Iloperidone label
Version not recorded · Effective date not recorded
Distribution Iloperidone has an apparent volume of distribution of 1340-2800 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f60b40-3fca-11de-8f56-0002a5d5c51b (opens source in a new tab)
Iloperidone label
Version not recorded · Effective date not recorded
Distribution Iloperidone has an apparent volume of distribution of 1340-2800 L.
Projected row 744
- Medicine slug
- imatinib
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:559dd8e5-11f9-70cd-3fb0-9f9eb8484a37 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e97f0238-b9da-46af-83a3-0826e39893e8 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9131b2ce-752d-3a30-e053-2a95a90adaab (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9de8d8b9-cf88-4960-82b7-89e5ceb7720e (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0291eca5-7a1d-4a79-30be-252224d96509 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d07ac08-962e-41a8-8a3c-50febc8c5f34 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9cfc301-3c7f-4910-8813-41dcb0b4ca69 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0611fc0-b217-4988-acd4-b8c629ce489b (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1debf3a0-7587-47d7-8ea6-e739698d7297 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be5b9047-155b-59ca-e053-2995a90ad3dc (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07764bf9-21b4-4e32-9d7e-e348f8e4291f (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7579620e-3748-46fa-8295-f9b47d0aa5b8 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:211ef2da-2868-4a77-8055-1cb2cd78e24b (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4e409f7-20b4-4c80-8a6a-f95995ffad78 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b7cc194-29e4-4484-a364-a1ac7d7d6cf5 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26658bb7-9ba1-a10e-e063-6394a90a172e (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Absorption Imatinib mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4acacbd-13f8-4a46-b615-b639a17f331f (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1787fad-3612-43e1-98fa-ce62361e0b3c (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82eb01e0-8685-4f06-8a72-7663e8ded38f (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c037022-7fc8-4b6e-9db3-427206c572b4 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a819a954-41c9-4d49-a74e-c8c4b338b22a (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e931c49-6c9f-41e2-a34b-5f01cd295b56 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e7ed4ef-24e3-4545-9a99-2e34c946e8e7 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fc5ec7b-98c4-4b1a-890c-be1343177dbd (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Mean absolute bioavailability is 98%.
Projected row 745
- Medicine slug
- imatinib
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 0.96
- Recorded readings
14.8 hours
- Numeric value
- 14.8
- Unit
- hours
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:559dd8e5-11f9-70cd-3fb0-9f9eb8484a37 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11 L/hr/m 2 in children vs. 10 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e97f0238-b9da-46af-83a3-0826e39893e8 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9131b2ce-752d-3a30-e053-2a95a90adaab (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9de8d8b9-cf88-4960-82b7-89e5ceb7720e (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0291eca5-7a1d-4a79-30be-252224d96509 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d07ac08-962e-41a8-8a3c-50febc8c5f34 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9cfc301-3c7f-4910-8813-41dcb0b4ca69 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0611fc0-b217-4988-acd4-b8c629ce489b (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1debf3a0-7587-47d7-8ea6-e739698d7297 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be5b9047-155b-59ca-e053-2995a90ad3dc (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs. 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07764bf9-21b4-4e32-9d7e-e348f8e4291f (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs. 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7579620e-3748-46fa-8295-f9b47d0aa5b8 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs.10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:211ef2da-2868-4a77-8055-1cb2cd78e24b (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4e409f7-20b4-4c80-8a6a-f95995ffad78 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b7cc194-29e4-4484-a364-a1ac7d7d6cf5 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs.10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4acacbd-13f8-4a46-b615-b639a17f331f (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1787fad-3612-43e1-98fa-ce62361e0b3c (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82eb01e0-8685-4f06-8a72-7663e8ded38f (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c037022-7fc8-4b6e-9db3-427206c572b4 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs. 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a819a954-41c9-4d49-a74e-c8c4b338b22a (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e931c49-6c9f-41e2-a34b-5f01cd295b56 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs.10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e7ed4ef-24e3-4545-9a99-2e34c946e8e7 (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fc5ec7b-98c4-4b1a-890c-be1343177dbd (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Apparent oral clearance was similar to adult values (11.0 L/hr/m 2 in children vs 10.0 L/hr/m 2 in adults), as was the half-life (14.8 hours in children vs 17.1 hours in adults).
18 hours
- Numeric value
- 18
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26658bb7-9ba1-a10e-e063-6394a90a172e (opens source in a new tab)
Imatinib label
Version not recorded · Effective date not recorded
Elimination The elimination half-life is approximately 18 hours for imatinib and 40 hours for the N-demethyl derivative metabolite (CGP74588), following oral administration in healthy volunteers.
Projected row 746
- Medicine slug
- imiquimod
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 11
- Source count
- 4
- Agreement rate
- 0.75
- Recorded readings
29.3±17.0 hours
- Numeric value
- 29.3
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d86eeb0e-70e0-4c72-aaa3-37daa1d8611e (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
Based on the plasma half-life of imiquimod observed at the end of the trial, 29.3±17.0 hours, steady-state concentrations can be anticipated to occur by Day 7 with once-daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28cd9b5b-680b-480f-b33d-9c5b52bbf03d (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
Based on the plasma half-life of imiquimod observed at the end of the trial, 29.3±17.0 hours, steady-state concentrations can be anticipated to occur by Day 7 with once-daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f2cbefd-f295-47e2-8a9e-3e7c5812c963 (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
Based on the plasma half-life of imiquimod observed at the end of the trial, 29.3±17.0 hours, steady-state concentrations can be anticipated to occur by Day 7 with once-daily dosing.
29.3±17 hours
- Numeric value
- 29.3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51913a5a-1cab-4b9e-b2c2-e0174062df73 (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
Based on the plasma half-life of imiquimod observed at the end of the trial, 29.3±17 hours, steadystate concentrations can be anticipated to occur by Day 7 with once-daily dosing.
Projected row 747
- Medicine slug
- imiquimod
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
9 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d86eeb0e-70e0-4c72-aaa3-37daa1d8611e (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
The median time to maximal concentrations (T max ) occurred at 9 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28cd9b5b-680b-480f-b33d-9c5b52bbf03d (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
The median time to maximal concentrations (T max ) occurred at 9 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51913a5a-1cab-4b9e-b2c2-e0174062df73 (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
The median time to maximal concentrations (Tmax) occurred at 9 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f2cbefd-f295-47e2-8a9e-3e7c5812c963 (opens source in a new tab)
Imiquimod label
Version not recorded · Effective date not recorded
The median time to maximal concentrations (T max ) occurred at 9 hours after dosing.
Projected row 748
- Medicine slug
- indapamide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
14 hours
- Numeric value
- 14
- Unit
- hours
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b5bb79-400d-e266-e063-6394a90abfd8 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:962b20df-88ff-4ab7-a900-135adb6c1d74 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59cd3331-7afe-432a-8b50-39533fd5f392 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a16fc49-7a36-4873-9652-194ebb0bac68 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a643c56-794a-4289-8390-5d76fa2709b3 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0687ed93-4761-4f9c-887d-95309c03f60e (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71feffd5-4056-2b53-e053-2995a90a5b73 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:deb83f97-6c61-4a09-bed6-18dcf1183405 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8a4ec2c-9d4b-482b-ad29-88185c96db74 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b55449f-4242-489d-8ba7-5baf4ba1a53a (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c678bc6b-a01b-4238-8bcb-490bc6d41d72 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:365d26ea-d02d-4fcf-9c99-54c251ef0483 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fe643f7-a1df-4e9a-9d45-f20b8512a04e (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The half-life of indapamide in whole blood is approximately 14 hours.
Projected row 749
- Medicine slug
- indapamide
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b5bb79-400d-e266-e063-6394a90abfd8 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:962b20df-88ff-4ab7-a900-135adb6c1d74 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a16fc49-7a36-4873-9652-194ebb0bac68 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a643c56-794a-4289-8390-5d76fa2709b3 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71feffd5-4056-2b53-e053-2995a90a5b73 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:deb83f97-6c61-4a09-bed6-18dcf1183405 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b55449f-4242-489d-8ba7-5baf4ba1a53a (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c678bc6b-a01b-4238-8bcb-490bc6d41d72 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:365d26ea-d02d-4fcf-9c99-54c251ef0483 (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fe643f7-a1df-4e9a-9d45-f20b8512a04e (opens source in a new tab)
Indapamide label
Version not recorded · Effective date not recorded
The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in the blood within 2 hours.
Projected row 750
- Medicine slug
- indigotindisulfonate
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
90%
- Numeric value
- 90
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73f246c4-b127-452e-856f-134b56cb8870 (opens source in a new tab)
Indigotindisulfonate label
Version not recorded · Effective date not recorded
mL (40 mg) BLUDIGO 5 mL (40 mg) General Information C max (CV%), μg/mL 6.33 (58.4) AUC 0-INF (CV%), μg·h/mL 1.15 (36.4) Distribution Mean (CV%) Volume of Distribution, L 10.7 (36.1) Protein Binding, in vitro About 90% Elimination Mean (CV%) Elimination Half-life, minutes 12 (34.1) Mean (CV%) Clearance, L/hour Urinary 7.08 (66.3) Total 40.2 (45.1) Metabolism Primary Metabolic Pathways Oxidative met
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b91c39d-5f15-4dcf-9d3d-b378470e6bd7 (opens source in a new tab)
Indigotindisulfonate label
Version not recorded · Effective date not recorded
variation BLUDIGO 5 mL (40 mg) General Information C max (CV%), μg/mL 6.33 (58.4) AUC 0-INF (CV%), μg·h/mL 1.15 (36.4) Distribution Mean (CV%) Volume of Distribution, L 10.7 (36.1) Protein Binding, in vitro About 90% Elimination Mean (CV%) Elimination Half-life, minutes 12 (34.1) Mean (CV%) Clearance, L/hour Urinary 7.08 (66.3) Total 40.2 (45.1) Metabolism Primary Metabolic Pathways Oxidative met
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=740Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.